

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for December 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

| Manufacturer | Product | Reference Product | Generic Name | Strength | Dosage Form | DIN |
|-------------------------|---------------------|--------------------------|--------------------------|-----------------|--------------------|------------|
| Sandoz Canada Inc. | Sandoz Posaconazole | Posanol | POSACONAZOLE | 100 mg | DR tablet | 02496259 |
| Jamp Pharma Corporation | Jamp-Gefitinib | Iressa | GEFITINIB | 250 mg | tablet | 02500663 |
| Nora Pharma | NRA-Fluoxetine | Prozac | FLUOXETINE HYDROCHLORIDE | 10 mg | capsule | 02503875 |